DIABETIC KIDNEY DISEASE IN 2017: A new era in therapeutics for diabetic kidney disease

    loading  Checking for direct PDF access through Ovid

Abstract

2017 saw the emergence of a new era in renoprotective medicine for diabetic kidney disease with reports of promising renal outcomes with the sodium-glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and canagliflozin from follow-up analyses of the EMPA-REG OUTCOME trial and the CANVAS Program, respectively, and with use of the glucagon-like peptide 1 (GLP1) agonist liraglutide in the LEADER trial.

    loading  Loading Related Articles